Business Context and Reporting Period
This Form 8-K was filed by Unum Therapeutics Inc. on January 18, 2019. The report details the entry into a material definitive agreement, specifically an amendment to an existing loan security agreement with Pacific Western Bank.
Key Financial Metrics
The filing does not provide specific numerical values for revenue, profit, cash flow, margins, or total debt. The document focuses exclusively on the structural terms of a credit facility amendment rather than reporting period financial performance.
Material Changes
On January 18, 2019, the Company entered into a "Second Amendment" to its Loan Security Agreement with Pacific Western Bank. The material changes include:
- Draw Deadline: Extended to June 30, 2019.
- Interest-Only Period: Extended until June 30, 2020, with a potential further extension to March 31, 2021, contingent upon raising additional capital.
- Repayment Terms: The 24-month interest and principal repayment period is now scheduled to commence following the end of the amended interest-only period.
- Depository Requirements: Primary depository requirements with Pacific Western Bank were increased.
- Fees: A facility fee was added to the agreement.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on future operations, or a discussion of general risks. The extension of the interest-only period is explicitly conditioned on the Company's ability to raise additional capital, indicating a liquidity dependency.
Investor Verification Checklist
- Verify the total outstanding principal balance under the amended Loan Security Agreement.
- Confirm the specific amount of the new facility fee and the increased depository requirements.
- Assess the Company's current progress in raising the additional capital required to extend the interest-only period to March 31, 2021.
- Review the full text of Exhibit 10.1 for any covenants or default provisions triggered by the amendment.